Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 9/20 | 0.61 |
| ▸ | TTR | P02766 | 4/20 | 0.58 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2078816 | 0.89 | TTR (0.57) | GPR35TTRCRHBPCRHR2CA12 | |
| SCHEMBL3858194 | 0.89 | TTR (0.67) | GPR35TTRCA12CA1CA2 | |
| SCHEMBL13113132 | 0.87 | TTR (0.51) | GPR35TTRCRHBPCRHR2CA12 | |
| SCHEMBL11741676 | 0.86 | MEN1 (0.52) | GPR35TTRCRHBPCRHR2CA12 | |
| SCHEMBL17744391 | 0.86 | GPR35 (0.65) | GPR35TTRCRHBPCRHR2CA12 | |
| SCHEMBL103341 | 0.86 | GPR35 (0.65) | GPR35TTRCRHBPCRHR2ALDH1A1 | |
| SCHEMBL103118 | 0.86 | TTR (0.50) | GPR35TTRCRHBPCRHR2CA12 | |
| SCHEMBL204106 | 0.82 | TTR (0.55) | GPR35TTRCRHBPCRHR2ALDH1A1 | |
| SCHEMBL5313614 | 0.82 | TTR (0.47) | GPR35TTRCRHBPCRHR2CA12 | |
| SCHEMBL20022338 | 0.81 | TTR (0.66) | GPR35TTRALDH1A1TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3936447-A | 7-Acylamino-desacetoxy-cephalosporanic acid esters and their production | BAYER AKTIENGESELLSCHAFT (DT) | 1976-02-03 | — | — | US | claimed |
| EP-3331861-A1 | PROCESS FOR THE PREPARATION OF 5-AMINO-QUINOLIN-2(1H)-ONES AND THEIR TAUTOMER FORMS 5-AMINO-QUINOLIN-2-OLS | Bayer Pharma Aktiengesellschaft (DE) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017025371-A1 | PROCESS FOR THE PREPARATION OF 5-AMINO-QUINOLIN-2(1H)-ONES AND THEIR TAUTOMER FORMS 5-AMINO-QUINOLIN-2-OLS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017025371-A1 | PROCESS FOR THE PREPARATION OF 5-AMINO-QUINOLIN-2(1H)-ONES AND THEIR TAUTOMER FORMS 5-AMINO-QUINOLIN-2-OLS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-16 | — | — | WO | disclosed |
| US-8901141-B2 | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| EP-2032583-B1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| EP-2240485-B1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8785460-B2 | Tricyclic compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8318761-B2 | Substituted arylsulfonamides as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8203001-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-7196087-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1708713-A1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D)(1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | F. Hoffman-la Roche AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| EP-1677791-A2 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060040997-A1 | Benzthiazole-3 oxides useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1589967-A1 | BENZTHIAZOLE-3 OXIDES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005067933-A1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-28 | — | — | WO | disclosed |
| US-20050165001-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2005-07-28 | — | — | US | disclosed |
| WO-2005044793-A2 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | WO | disclosed |
| WO-2004067000-A1 | BENZTHIAZOLE-3 OXIDES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2004-08-12 | — | — | WO | disclosed |
| US-3936447-A | 7-Acylamino-desacetoxy-cephalosporanic acid esters and their production | BAYER AKTIENGESELLSCHAFT (DT) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040997-A1 | Benzthiazole-3 oxides useful for the treatment of proliferative disorders | CBR3, FGFR3, CCNH | GPR35 2167/4885TTR 2904/4885CRHBP 3176/4885 |
| US-20050165001-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | NQO2, MLX, CYP4X1 | GPR35 3066/4885TTR 4767/4885CRHBP 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.